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Two cases, probably related, of fungemia due to Scedosporium prolificans are described in two patients with acute
leukemia. Both were admitted to the hematological ward in nearby rooms, during building work
in the hospital. After a previous bacterial sepsis in the neutropenic phase, which improved with antibiotic
treatment, the respiratory status in both patients deteriorated presenting acute dypsnea, with a lung infiltrate
in one of them. A few hours later both patients died. Blood cultures were positive for S. prolificans.
These two new cases of S. prolificans infection stress the importance of awareness of this emerging pathogen in
patients who suffer a hematologic malignancy during the neutropenic phase, especially if building
work is taking place in the hospital.
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In the last two decades, the use of aggressive treatment and
techniques such as transplants, chemotherapy, catheter implants
and others to prolong the lives of patients, and the existence of
HIV, have created a new group of patients who are especially
susceptible to fungal infections, and consequently the morbidity
and mortality due to these organisms have witnessed notable
increases.
In 1984, Malloch and Salkin described the first case of human
infection due to Scedosporium inflatum [1]. Recent DNA analyses
have demonstrated that this fungus is identical to Lomentospora
prolificans, a species isolated in Belgium by Hennebert and Desai
[2], and, according to the current rules of botanical nomen-
clature, it was renamed Scedosporium prolificans. The natural
habitat of this fungus is not well known; it has been isolated
in soil from flower pots and also from cats and horses [3,4]. In
humans, the clinical spectrum of S. prolificans ranges from
asymptomatic colonisation to severe disseminated infections.
Most of these latter cases have been associated with immuno-
compromised patients, especially those with profound neutro-
penia. Contaminated air-conditioning systems and renovation
inside hospitals have been related to nosocomial infections
produced by several opportunistic fungi such as Aspergillus
spp. [5]; a report has recently been published on the first possible
outbreak of nosocomial infection due to S. prolificans [6].
Our study describes two new cases of fatal S. prolificans
infection in two leukemic patients coinciding with rebuilding
work in the hospital.
PATIENTS AND METHODS
Two leukemic patients had fungemia due to S. prolificans during
profound neutropenia. Both cases were detected in the same
ward over a period of 20 days and coincided with reconstruction
work at the hospital. Blood samples were inoculated into
aerobic and anaerobic bottles (Bactec Plus/F aerobic and
anaerobic; Becton Dickinson, Spacks, MD, USA) and processed
in the Bactec 9120 automatic system for 7 days. The bottles
were subcultured on blood agar and Sabouraud dextrose agar
(Difco, Detroit, MI, USA) when the system detected growth.
Environmental samples were taken from each of the rooms to
identify the reservoir. Saline-moistened sterile cotton swabs
were used for collecting samples from walls, floors, the surfaces
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of furniture and air-conditioning ducts, but no air volumetric
samples were taken. The swabs were cultured on blood agar,
Sabouraud dextrose agar without and with amphotericin B at a
final concentration of 10 mg/L, and Mycobiotic agar (Difco).
The plates were incubated at 30 8C for 10 days. The colonies of
fungi which grew in the culture medium were identified
according to standard methods. In vitro susceptibility testing
of the strains isolated from both patients against amphotericin B,
ketoconazole, itraconozale, flucytosine, fluconazole, micona-
zole and voriconazole was performed in the Centro Nacional de
Microbiologı´a in Majadahonda using a modification of the
microdilution method proposed by the National Committee
for Clinical Laboratory Standards (NCCLS) [7].
CASE REPORTS
Case 1
A 34-year-old woman had been treated for acute myeloblastic
leukemia in October 1997. After complete remission, the
patient was readmitted in December and was treated with a
cycle of chemotherapy with idarubicine and cytarabine. Intra-
venous fluconazole (400 mg/day) was administered as prophy-
laxis. Nine days later, during profound neutropenia (leukocyte
count 0.1 109/L and thrombocyte count 20 109/L) and
fever of 39 8C, the patient had diffuse abdominal pain. Blood
cultures revealed Pseudomonas aeruginosa. Treatment with piper-
acillin–tazobactam plus amikacin was instituted. After 48 h of
therapy, the patient’s clinical condition improved but she con-
tinued to be febrile. Candida albicans (fluconazole MIC¼
0.5 mg/L) was isolated in another blood culture. Faced with
this episode of breakthrough candidemia during treatment with
fluconazole, we substituted it with liposomal amphotericin B
(3 mg/kg/day). Four days later, the patient presented dyspnea
and hemoptysis. A chest radiograph revealed an infiltrate in
the left lung. A further blood analysis revealed, among others,
the following results: leukocyte count 0.1 109/L, PCO2
20.9 mmHg, PO2 88 mmHg, and 96% oxygen saturation.
Several blood cultures were taken, and several hours later the
patient’s dyspnea worsened, the oxygen saturation fell to 54%,
and she died. These last blood cultures were positive for
S. prolificans. A postmortem study was not authorised by the
family.
Case 2
A 20-year-old woman was diagnosed in March 1996 with acute
lymphoblastic leukemia and treated with chemotherapy. In
January 1998 she was readmitted due to a fever of several days’
duration. There was a bone marrow relapse with a white blood
cell count of 0.5 109/L. A few hours later, the patient
developed septic shock and renal function deterioration.
Escherichia coli and P. aeruginosa were isolated in blood cultures,
and treatment with piperacillin–tazobactam plus amikacin
was initiated, with some improvement in her condition. In
the following week chemotherapy was commenced, and, due to
the persistence of the fever, amphotericin B (1 mg/kg/day) was
added to the treatment and piperacillin–tazobactam was
replaced by imipenem. Two days later, the patient suffered in-
tense dyspnea with severe hypoxemia. Chest roentgenographic
findings were normal. She died a few hours later due to
respiratory failure. Two blood cultures (Bactec) obtained 24 h
before death were positive for S. prolificans. A postmortem study
was not authorised by the family.
RESULTS AND DISCUSSION
The three blood cultures taken from the first patient were
positive between 59 and 67 h, and the two from the second
patient between 48 and 60 h. On subculture, S. prolificans grew
on blood agar and Sabouraud dextrose after 24–48 h. The
colonies were greenish-brown in color with a woolly appear-
ance. Microscopic examination using lactophenol–cotton blue
revealed thin-walled hyphae with ovoid conidia spread
throughout the hyphae and in clusters at the apex of conidio-
phores with the distinctive swollen base characteristic of S.
prolificans. The environmental surface cultures were negative for
S. prolificans, although there was growth of other environmental
fungi, such as aspergilli.
Susceptibility tests revealed the same MICs (mg/L) for both
strains for amphotericin B (16), ketoconazole (32), itraconazole
(16), flucytosine (128), fluconazole (128) and miconazole (128).
A dilution difference existed between the MICs (32 and 64) of
voriconazole.
Although infections caused by S. prolificans are not frequently
seen, they are extremely serious and, to our knowledge, only
one patient in whom this fungus was isolated in the blood has
survived the infection when granulocytopenia subsided [8].
Spain is the country in which most cases have been published,
most of them appearing in the excellent review by Berenguer
et al. [7], in which 16 patients from different hospitals and with
very serious infections are described. The main predisposing
factor for acquiring the infection is the presence of neutropenia,
usually associated with serious blood disorders and chemother-
apy treatment, although cases with different underlying ill-
nesses, such as renal transplant [9], lung transplant [10] and
AIDS [11], have been described. Our two cases presented with
the triad of leukemia, chemotherapy and neutropenia with fatal
outcome. Infection usually starts during or after treatment with
broad-spectrum antibiotics and amphotericin B, as happened in
our two patients. The most frequent clinical manifestations are
fever and dyspnea with pulmonary infiltrates in the chest X-ray.
These three conditions were fulfillled in our first patient, while
the second one had fever and dyspnea and a normal chest X-ray,
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as in the case described by Nenoff et al. [11]. In other less
frequent cases, alterations of the central nervous system and skin
lesions have been reported. Our two infections occurred over a
short period of time, with the patients in nearby rooms, and
during rebuilding work near the hematologic ward. These facts
would suggest an epidemic context, although the fungus was
not isolated from the environmental samples, perhaps due to a
lack of sensitivity in the methods used, since no air samples were
taken and materials and soil used in the reconstruction work at
the hospital were not investigated. This same situation occurred
in another possible outbreak of infection due to S. prolificans [6]
and in a nosocomial infection reported in 1996 [12]. The
isolation of the fungus from air samples taken in rooms where
patients infected by S. prolificans were admitted has been docu-
mented by Dura´n et al. [13]. S. prolificans is detected in blood,
unlike Aspergillus spp. infections. With use of the Bactec system,
the detection time in Berenguer’s series [7] ranged from 9 to
15 days. Thus, on many occasions, the diagnosis occurred after
the death of the patient. Our two cases differ notably with
regard to detection time, since the blood cultures were positive
between 48 and 67 h, which is a similar time to that described
for the Isolator system [6].
The two strains of S. prolificans, like others described pre-
viously, were resistant to all the antifungal agents tested, and this
makes prognosis even bleaker. Recently, a case has been
described of favorable outcome in a neutropenic patient with
pneumonia, treated with liposomal amphotericin, although the
strain was also resistant in vitro to the latter [14]. However, the
first of our patients died in spite of treatment with 3 mg/kg per
day of liposomal amphotericin 4 days before the appearance of
her respiratory problems and pulmonary infiltrate.
These two new cases of infection due to S. prolificans stress the
importance of the awareness of this emerging pathogen in
patients who suffer a hematologic malignancy during the
neutropenic phase, especially if rebuilding work is taking place
in the hospital.
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